Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth’s farm team

Executive Summary

Wyeth's "most interesting" developmental project "from a scientific point of view" is the anti-GDF8 antibody MYO-029, in Phase I as a potential treatment for type II diabetes and for wasting diseases, CEO Robert Essner told the J.P. Morgan H&Q conference Jan. 7 in San Francisco. The antibody targets myostatin, which is believed to decrease muscle mass and increase fat and glucose levels in the blood. Essner showed a picture of the Belgian Blue Bull, a species that naturally lacks GDF8; it is "an animal that is massive, is muscled, is low fat, but otherwise lives a very healthy normal lifecycle." If the compound advances in development, it could give Wyeth a new barnyard symbol to supplant the pregnant mares that provide the raw material for the company's flagship conjugated estrogens line...

You may also be interested in...

QUOTED. 9 March 2021. Matthew Trerotola.

Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

US FDA Addresses PFAS In Cosmetics, Aiming To Close Data Gaps

Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts